



SKINVIVE™ BY JUVÉDERM®

Lasting Glow*



The **ONLY** hyaluronic acid (HA) injectable treatment delivering long-lasting,* deep† hydration for up to 9 months following a single treatment^{1,2,‡,§}

Real patient.
Results may vary.

SKINVIVE™ by JUVÉDERM® injectable gel is indicated for intradermal injection of the face (cheek, forehead) and neck, by filling of superficial cutaneous depressions such as fine lines and for additional improvement of hydration.³

* Based on a search of published clinical studies of injectable HA treatments in March 2023. A duration of 9 months of skin hydration was established with SKINVIVE™.²

† Skin hydration was measured using the MoistureMeterD instrument with the XS 5 and S 15 probes (depth of effective measurement: 0.5 and 1.5 mm, respectively).¹

‡ Long lasting is up to 9 months following a single treatment.¹

§ Instrument measures of skin hydration, smoothness, and skin deformation parameters were performed on the cheek, forehead, and neck of one side of the face on Day 0 and at 30 days after initial treatment (before touch up), Months 1, 4, 6, and 9 after the last treatment, and Month 1R. Skin hydration was measured using the MoistureMeterD instrument (n=131) and top-up treatment administered at Day 30 (n=31).¹



SKINVIVE™ is the **ONLY** hyaluronic acid (HA) microdroplet injectable treatment delivering long-lasting,* deep† hydration for up to 9 months following a single treatment^{1,2,‡,§}

Lasting
Glow*



G

Gives patients a lasting,* hydrated^{1,‡} glow^{4,†} they'll want to talk about

L

Leverages the power of HA and boosts levels of Aquaporin-3, a biological marker for hydration, to deliver deep hydration from within⁵

O

Only intradermal microdroplet injectable treatment to deliver improvements in face and neck skin texture for up to 6 months¹ and hydration up to 9 months¹ following a single treatment

W

Well-established safety profile¹, with minimal downtime⁶ & can be flexibly used in combination with other aesthetic treatments⁷

SKINVIVE™ 360° Partnership

Holistic support to help you achieve SKINVIVE™ success in your practice



* Based on a search of published clinical studies of injectable HA treatments in March 2023. A duration of 9 months of skin hydration was established with SKINVIVE™.¹

† Skin hydration was measured using the MoistureMeterD instrument with the XS 5 and S 15 probes (depth of effective measurement: 0.5 and 1.5 mm, respectively).¹


‡ Long lasting is up to 9 months following a single treatment.¹

§ Instrument measures of skin hydration, smoothness, and skin deformation parameters were performed on the cheek, forehead, and neck of one side of the face on Day 0 and at 30 days after initial treatment (before touch up), Months 1, 4, 6, and 9 after the last treatment, and Month 1R. Skin hydration was measured using the MoistureMeterD instrument (n=131) and top-up treatment administered at Day 30 (n=31).¹

The demand for skin quality treatment is growing significantly⁸



In recent years, there has been a dramatic increase in online discussions around⁸




Consumers want a convenient skin quality treatment to address skin hydration, smoothness and achieve glowing skin.⁸

Hydration is an important component of skin quality



Skin quality is a collection of desirable skin attributes that encompasses how skin looks, feels, and moves.

SKIN QUALITY CONCERNS



Although patients have a variety of skin quality treatment options, there is an opportunity for a treatment that can provide long lasting, deep hydration in one session.¹

Did you know?

Hydration is at the centre of skin quality, impacting visual, topographical and mechanical attributes.¹⁰


Reasons patients choose SKINVIVE™ by JUVÉDERM®



Gabija

Concerned with early signs of aging, like texture and dullness

Real patient. Results may vary.



Nikola

Interested in skin quality modalities that don't require a series of treatments and offer minimal to no downtime


Real patient. Results may vary.



Jennifer

"Skintelligent" patient who is receptive to products that contain hyaluronic acid and that help hydrate the skin

Real patient. Results may vary.



Tia

Looking for a skin quality treatment that can be used on any skin tone

Real patient. Results may vary.

Meet SKINVIVE™

SKINVIVE™ by JUVÉDERM® is the **ONLY** hyaluronic acid (HA) injectable treatment delivering long-lasting,* deep† hydration for up to 9 months and improvements in skin texture for up to 6 months following a single treatment^{1,2,‡,§}



HYDRATING SKIN QUALITY TREATMENTS^{11,12}

EPIDERMAL


- Topical hydrators (e.g. - HA[§] Rejuvenating Hydrator)

SKINMEDICA®



SKINVIVE™
BY JUVÉDERM®

The only hydrating injectable treatment that works deep† in the dermis in one session¹



OTHER SKIN QUALITY TREATMENTS^{13,14}

EPIDERMAL

- Chemical peels
- Microdermabrasion
- Medical grade skincare/Rx topicals

SKINMEDICA®

DERMAL

- Energy-based treatments
- Professional microneedling

With its long-lasting, ‡ deep† hydration,^{1,§} SKINVIVE™ is the foundation to any treatment plan[¶] for patients seeking healthy-looking skin¹³

* Based on a search of published clinical studies of injectable HA treatments in March 2023. A duration of 9 months of skin hydration was established with SKINVIVE™.²


† Skin hydration was measured using the MoistureMeterD instrument with the XS 5 and S 15 probes (depth of effective measurement: 0.5 and 1.5 mm, respectively).¹

‡ Long lasting is up to 9 months following a single treatment.¹


§ Instrument measures of skin hydration, smoothness, and skin deformation parameters were performed on the cheek, forehead, and neck of one side of the face on Day 0 and at 30 days after initial treatment (before touch up), Months 1, 4, 6, and 9 after the last treatment, and Month 1R. Skin hydration was measured using the MoistureMeterD instrument (n=131) and top-up treatment administered at Day 30 (n=31).¹

¶ SKINVIVE™ should not be used simultaneously with laser treatment, deep chemical peels or dermabrasion. For surface peels, it is recommended not to inject the product if the inflammatory reaction generated is significant.³

SKINVIVE™ is the **ONLY** HA injectable that can give your patients up to 9 months of deep* hydration and up to 6 months of improvements in skin texture in a single treatment^{1,2,†}



Hydration with SKINVIVE™ lasts for up to 9 months^{1,‡} —unlike any other product on the market



The convenience of lasting[‡] results^{1,14}

91%
n=131

of patients were happier[†] with their skin vs baseline at Month 1 and results persisted to 76% at Month 9 (n=127)^{4,‡}



After one treatment session, patients can enjoy results lasting up to 9 months¹ with minimal downtime^{6,§}



Treatment typically takes just 5-15 minutes, making it convenient for both patients and practitioners

SKINVIVE™ offers your patients lasting* results¹ with minimal downtime⁶ and without a series of treatments¹

* Skin hydration was measured using the MoistureMeterD instrument with the XS 5 and S 15 probes (depth of effective measurement: 0.5 and 1.5 mm, respectively).¹

† Instrument measures of skin hydration, smoothness, and skin deformation parameters were performed on the cheek, forehead, and neck of one side of the face on Day 0 and at 30 days after initial treatment (before touch up), Months 1, 4, 6, and 9 after the last treatment, and Month 1R. Skin hydration was measured using the MoistureMeterD instrument (n=131) and top-up treatment administered at Day 30 (n=31).¹


§ $p < 0.001$.¹

|| $p \leq 0.012$.¹

‡ Based on a search of published clinical studies of injectable HA treatments in March 2023. A duration of 9 months of skin hydration was established with SKINVIVE™.²

Patients reported a lasting Glow^{1*}

Patients reported higher satisfaction with their skin after SKINVIVE™ by JUVÉDERM® treatment, and saw significant improvement with how glowing, hydrated, refreshed, and healthy their skin looked[†]



* Glow was recorded as radiance within the validated FACE-Q questionnaire.

† As measured using the Satisfaction with Skin module of the validated FACE-Q questionnaire.

91%
patient satisfaction
1 month after
treatment⁵

9 in 10
would recommend
SKINVIVE™ to
a friend^{4,‡}

‡ At Month 9, 86.6% of patients (n=127) would recommend SKINVIVE™ to a friend.⁴


Leverage the power of HA and boost levels of AQP3^{15,*} to deliver deep[†] hydration^{1,‡}

SKINVIVE™ delivers hydration through multiple mechanisms

Hyaluronic acid¹⁵ (HA)




- Linear polysaccharide molecule important for hydration and structure
- HA, the key ingredient in SKINVIVE™³, can attract and bind more than 1,000 times its weight in water^{5,16}



Aquaporin-3 (AQP3)¹⁵



- Found in the epidermis
- Transports water and glycerol into and out of cells
- Critical for maintaining hydration in the skin



Together, these two effects may contribute to deep dermal hydration with SKINVIVE™

Image is for illustrative purposes only. Image source: Allergan Aesthetics, an AbbVie company. Allergan Medical Institute

Did you know?

The expression of aquaporin-3 channels significantly decreases with age and sun exposure, leading to skin dryness.

With a well-established safety profile¹, with minimal downtime⁶, SKINVIVE™ can be flexibly used in all skin types and in combination with other aesthetic treatments⁷

All treatment-related AEs were mild to moderate severity³

ISRs were typically mild or moderate, with most of them resolved within 1 week of each treatment^{3,4}

Most common injection-site reactions (>80%, after first treatment) were: redness, swelling, tenderness, bruising, firmness, lumps/bumps and pain after injection³

Well-tolerated in treatment areas (cheek, forehead & neck)³

Nearly all subjects reported being able to return to normal daily social activities a day after injection³

Treatment-related AEs^{3,4}

Event, n (%) ³	Subjects N=131
Treatment related AEs, n (%)	20 (15.3)
Injection site mass	12 (9.2)
Injection site bleeding	4 (3.1)
Injection site haematoma	3 (2.3)
Injection site erythema	1 (0.8)
Injection site nodule	1 (0.8)

95-100%
of patients were able to return to their normal social activities 1 day after treatment⁴

SKINVIVE™ can be used effectively with other treatment modalities as part of a combination treatment plan⁷



- Retrospective real-world study of **736** patients⁷
- A total of **1,577** SKINVIVE™ treatments⁷
- Treatments performed in combination with SKINVIVE™:
 - Neuromodulators, fillers, complexion-based treatments, skin-tightening treatments and other modalities⁷
 - Typically, **mild** and **self-limited** injection-site reactions⁷

What to know about the Glow^{4,17*}

If you are ready to give your patients skin that is...

SMOOTH



Significant, lasting improvement in skin smoothness of the cheeks*

HYDRATED



Increased hydration using the only microdroplet treatment that hydrates skin from within in a single treatment

GLOWING



Glow for up to 9 months^{4,17*}

LASTING



Lasting results without the need for a series of treatments[†]

...it's time to offer

 **SKINVIVE**[™] BY JUVÉDERM[®]

* Lasts 9 months with optimal treatment.

Important Safety Information

INDICATIONS

SKINVIVE™ by JUVÉDERM® is indicated for treatment of the face (cheek and forehead) and neck, by filling of superficial cutaneous depressions such as fine lines and for additional improvement of hydration.³

IMPORTANT SAFETY INFORMATION

WARNINGS

- Check the expiry date on the product label.
- In the event that the content of a syringe shows signs of separation and/or appears cloudy, do not use the syringe.
- Do not re-use. Sterility of this device cannot be guaranteed if the device is re-used.
- Do not re-sterilise.
- For the needles (CE 0123 TSK Laboratory, Japan):
 - Used needles must be thrown away in the appropriate containers. Do the same for the syringes. Please consult the current applicable directives to ensure their correct elimination.
 - Never try to straighten a bent needle; throw it away and replace it.

PRECAUTIONS

- SKINVIVE™ by JUVÉDERM® is indicated only for intra-dermal injections.
- Medical practitioners must take into account the fact that this product contains lidocaine.
- As a matter of general principle, injection of a medical device is associated with a risk of infection. Standard precautions associated with injectable materials shall be followed.
- There is no available clinical data about injection of SKINVIVE™ by JUVÉDERM® into an area which has already been treated with a non-ALLERGAN dermal filler.
- It is recommended not to inject into a site which has been treated with a permanent implant.
- No clinical data is available regarding the efficiency and tolerance of SKINVIVE™ by JUVÉDERM® injections in patients having a history of, or currently suffering from, autoimmune disease or autoimmune deficiency or being under immunosuppressive therapy. The medical practitioner shall therefore decide on the indication on a case-by-case basis, according to the nature of the disease and its corresponding treatment, and shall also ensure the specific monitoring of these patients. In particular, it is recommended that these patients undergo a preliminary skin testing for hypersensitivity, and to refrain from injecting the product if the disease is active.
- There is no available clinical data concerning the tolerance of SKINVIVE™ by JUVÉDERM® injection in patients presenting a history of severe and/or multiple allergies. The medical practitioner shall therefore decide on the indication on a case-by-case basis, according to the nature of the allergy, and shall also ensure the specific monitoring of these at-risk patients. In particular, the decision may be taken to propose a skin testing for hypersensitivity or suitable preventive treatment prior to any injection. In case of history of anaphylactic shock, it is recommended not to inject the product.
- Patients showing a history of streptococcal disease (recurrent sore throats, acute rheumatic fever) shall be subjected to a skin testing for hypersensitivity before any injection is administered. In the event of acute rheumatic fever with heart complications, it is recommended not to inject the product.
- Patients on anti-coagulation medication or using substances that can prolong bleeding (warfarin, acetylsalicylic acid, nonsteroidal anti-inflammatory drugs, or other substances known to increase coagulation time such as herbal supplements with garlic or ginkgo biloba, etc.) must be warned of the potential increased risks of bleeding and haematomas during injection.
- There is no data available regarding the safety of injecting greater amount than 20 mL of ALLERGAN dermal fillers per 60 kg (130 lbs) body mass per year.
- Due to presence of lidocaine, the combination of SKINVIVE™ by JUVÉDERM® with certain drugs that reduce or inhibit hepatic metabolism (cimetidine, beta-blockers, etc.) is not recommended.
- Due to presence of lidocaine, SKINVIVE™ by JUVÉDERM® should be used with caution in patients showing symptoms of cardiac conduction disorders.
- Please recommend that the patient not use any makeup during the 12 hours following the injection treatment and that any extended exposure to the sun, UV rays and temperatures below 0°C be avoided, as well as any sauna or hammam sessions during the two weeks following the injection treatment.
- The composition of this product is compatible with fields used for magnetic resonance imaging.

UNDESIRABLE EFFECTS

The patients must be informed that there are potential side effects associated with implantation of this product, which may occur immediately or may be delayed. These include, but are not limited to:

- Inflammatory reactions (redness, oedema, erythema, etc.) which may be associated with itching and/or pain on pressure and/or paresthesia, occurring after the injection. These reactions may last for a week.
- Haematomas.
- Induration or nodules at the injection site.
- Staining or discolouration of the injection site might be observed, especially when HA dermal filler is injected too superficially and/or in thin skin (Tyndall effect).
- Poor effect or weak filling effect.
- Rare but serious adverse events associated with intravascular injection of dermal fillers in the face and tissue compression have been reported and include temporary or permanent vision impairment, blindness, cerebral ischemia or cerebral hemorrhage, leading to stroke, skin necrosis and damage to underlying structures. Immediately stop the injection if a patient exhibits any of the following symptoms, including changes in the vision, signs of stroke, blanching of the skin or unusual pain during or shortly after the procedure. Patients should receive prompt medical attention and possibly evaluation by an appropriate medical practitioner specialist should an intravascular injection occur. Abscesses, granuloma and immediate or delayed hypersensitivity after hyaluronic acid and/or lidocaine injections have also been reported. It is therefore advisable to take these potential risks into account.
- Patients must report inflammatory reactions which persist for more than one week, or any other side effect which develops, to their medical practitioner as soon as possible. The medical practitioner should use an appropriate treatment.
- Any other undesirable side effects associated with injection of SKINVIVE™ by JUVÉDERM® must be reported to the distributor and/or to the manufacturer.

FOR COMPLETE SAFETY INFORMATION

Refer to the Directions for Use (DFU) for SKINVIVE™ by JUVÉDERM® for important information relating to contraindications, precautions, undesirable effects, and methods of use which now have been discussed in this piece.

The DFU for SKINVIVE™ by JUVÉDERM® is available by calling AbbVie at 1-800-668-6424 or by visiting www.allerganaesthetics.ca/en/our-products/medical-devices.

Adverse events should be reported to your local regulatory authority and AbbVie office.

References:

1. Niforos F, et al. *Clin Cosmet Investig Dermatol*. 2019;12:791-98.
2. Allergan Aesthetics. Unpublished data. SKINVIVE™ by JUVÉDERM® – 9-month duration of skin hydration in clinical trials. March 2023.
3. SKINVIVE™ by JUVÉDERM® Directions for Use, September 2022.
4. Ogilvie P, et al. *J Cosmet Dermatol*. 2020;19(5):1065-1070.
5. Safa M, et al. *Clin Cosmet Investig Dermatol*. 2022;15:411-42.
6. Ogilvie P, et al. *Clin Cosmet Investig Dermatol*. 2020;13:267-74.
7. Zarbafian M, et al. *Dermatol Surg*. 2022;48(3):369-72.
8. Allergan Aesthetics. Data on file. REF-100241. Skin Health Media Statistics. August 2022.
9. Allergan Aesthetics. Data on file. Consumer Beauty Insights Survey 2021. August 2021.
10. Humphrey S, et al. *Dermatol Surg*. 2021;47(7):974-81.
11. Narurkar VA, et al. *J Drugs Dermatol*. 2016;15(1):s[CV1] 24-37.
12. Tendler A. Artisan Skin and Laser Center. August 18, 2016. Accessed May 19, 2023. <https://artisanskinandlaser.com/blog/microdermabrasion-with-serum-infusion-enter-fall-looking-your-best>.
13. Baumann L. *J Pathol*. 2007;211:241-51.
14. Data on File. Allergan Aesthetics. Irvine, California.
15. Nakab L, et al. *Plast Reconstr Surg Glob Open*. 2020;8(3):e2723.
16. Bogdan Allemann I, et al. *Clin Interv Aging*. 2008;3(4):629-34.
17. Chiu A, et al. *Aesthet Surg J*. 2023.